

Stevanato Group signs an Exclusive Agreement with Haselmeier to License Axis-D Pen-injector Technology and Intellectual Property for the Therapeutic Area of Diabetes Care

Stevanato Group, an Italian-based producer of glass primary packaging and global leader in providing integrated capabilities and solutions for combination products and **Haselmeier**, a Swiss- and German-based developer and manufacturer of innovative self-injection devices, today announced an exclusive **agreement to license the Axis-D pen-injector technology and intellectual property (IP) in the Therapeutic Area of Diabetes Care.**

The **Axis-D pen-injector** was designed and **developed by Haselmeier together with its partners**, and a version of this pen-injector is currently on the market today having been launched by a major pharmaceutical company and approved for use, among others, by the European Medical Agency (EMA) and the US Food and Drug Administration (FDA). Stevanato Group plans to utilize this technology and IP to provide a new pen injector to **support the needs of diabetes patients** all over the world. Once the design for the device is finalized, it **will be produced at one of Stevanato Group's manufacturing facilities based on their extensive tooling, molding and assembly expertise. Sub-assembly and final assembly** equipment will be provided by Stevanato Group operations in Denmark.

Frédéric Gabriel, Chief Innovation Officer at Haselmeier, said: "We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in Diabetes. Stevanato Group has demonstrated in past years a consistent development strategy coupled with **unique integrated capabilities** and is able to leverage Haselmeier's pen injection platform to bring it to the next level. Such **platform has already been proven in the market, from an IP, performance and user perspective.** It also demonstrates Haselmeier's strategic orientation to exploit its IP over various paths, either with its' own development and manufacturing capabilities or together with a strategic partner."

"Consistent with its vision **Stevanato Group always welcomes strategic agreements with key players** in the market **to broaden its global capabilities**" said **Paolo Patri**, Chief Technology Officer at Stevanato Group "We value our relationship with Haselmeier as a device technology partner. With this agreement, we continue to **expand our portfolio of devices for patients suffering from diabetes.** This complements ongoing work on our award winning 1ml cartridge-based wearable device, which will give our biopharmaceutical partners the opportunity to provide patients with both standard and alternative treatment solutions with such devices."

For more information, please contact:

Steven Kaufman, steven.kaufman@stevanatogroup.com

Frédéric Gabriel, f.gabriel@haselmeier.com

About Stevanato Group

Established in 1949, Stevanato Group is the world's largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group is able to offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership.

For more information please visit www.stevanatogroup.com

About Haselmeier

As expert in subcutaneous drug delivery systems for self-administration, Haselmeier provides innovative and award-winning individual system solutions to support patients for a successful therapy. Haselmeier primarily works with pharmaceutical and biotechnology companies by developing and manufacturing traditional and connected pens and auto-injectors that are convenient, precise in dosing, and enable an enhanced patient experience to support therapy efficiency. Haselmeier covers all steps – from design to planning and industrialization – in the creation of high-quality self-injection systems. Next year, the well-established company will be able to look back on a 100-year-old success story. Spread across eight global locations on three different continents, the Haselmeier Group employs a workforce of more than 240 people.

For more information please visit www.haselmeier.com